Table 4.
Development of complications/comorbidities among new-onset T2D patients
| Complications | Early-onset T2D (N = 21,347) | Late-onset T2D (N = 300,676) | P-Value |
|---|---|---|---|
| New CVD onset | |||
| Number of patients (N) | 4,300(20.1) | 120,725(40.2) | < 0.001 |
| Male (N, %) | 2,883 (67.0) | 61,375 (50.8) | < 0.001 |
| Days after diabetes onset (M, IQR) | 301.0 [51.0, 750.0] | 227.0 [38.0, 651.0] | < 0.001 |
| New CKD onset | |||
| Number of patients (N) | 389(1.8) | 15,082(5.0) | < 0.001 |
| Male (N, %) | 266 (68.4) | 8,063 (53.5) | < 0.001 |
| Days after diabetes onset (M, IQR) | 423.0 [111.0, 931.0] | 428.0 [109.0, 890.0] | 0.724 |
| New Hypertension onset | |||
| Number of patients (N) | 4,870 (22.8) | 95,691 (31.8) | < 0.001 |
| Male (N, %) | 3,539 (72.7) | 57,495 (60.1) | < 0.001 |
| Days after diabetes onset (M, IQR) | 163.0 [28.0, 611.0] | 278.0 [43.0, 735.0] | < 0.001 |
| New Hyperlipidemia onset | |||
| Number of patients (N) | 7,613(35.7) | 113,952(37.9) | < 0.001 |
| Male (N, %) | 4,981 (65.4) | 58,121 (51.0) | < 0.001 |
| Days after diabetes onset (M, IQR) | 114.0 [19.0, 537.0] | 232.0 [34.0, 680.0] | < 0.001 |